Novavax, Inc. (NASDAQ:NVAX) has received an average recommendation of “Hold” from the fourteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $6.09.
A number of research firms have commented on NVAX. Chardan Capital reaffirmed a “neutral” rating and set a $1.50 price objective on shares of Novavax in a research report on Thursday. Piper Jaffray Companies reaffirmed a “hold” rating and set a $1.50 price objective on shares of Novavax in a research report on Wednesday. BidaskClub raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Thursday. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 price objective on shares of Novavax in a research report on Friday, July 21st. Finally, Zacks Investment Research cut shares of Novavax from a “buy” rating to a “hold” rating in a research report on Friday, June 9th.
In other news, insider Stanley C. Erck bought 50,000 shares of the company’s stock in a transaction dated Thursday, May 11th. The stock was bought at an average price of $0.84 per share, with a total value of $42,000.00. Following the completion of the acquisition, the insider now owns 128,279 shares of the company’s stock, valued at $107,754.36. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have bought 105,000 shares of company stock valued at $90,800 in the last three months. Insiders own 4.00% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Canada Pension Plan Investment Board bought a new stake in Novavax during the first quarter worth $157,000. HighTower Advisors LLC increased its position in shares of Novavax by 3.8% in the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 5,250 shares during the last quarter. American International Group Inc. increased its position in shares of Novavax by 7.1% in the first quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 10,965 shares during the last quarter. KCG Holdings Inc. increased its position in shares of Novavax by 161.0% in the first quarter. KCG Holdings Inc. now owns 178,797 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 110,292 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in shares of Novavax by 2.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 203,996 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 5,704 shares during the last quarter. 50.04% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/07/28/novavax-inc-nasdaqnvax-given-average-rating-of-hold-by-brokerages.html.
Novavax (NVAX) traded down 5.9216% during trading on Friday, reaching $0.9596. 12,475,435 shares of the company traded hands. The company’s market cap is $271.18 million. The company’s 50-day moving average is $1.18 and its 200 day moving average is $1.18. Novavax has a 12 month low of $0.73 and a 12 month high of $8.49.
Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02. Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. The firm had revenue of $5.68 million during the quarter, compared to analysts’ expectations of $6.17 million. During the same period in the previous year, the business posted ($0.29) earnings per share. The company’s revenue for the quarter was up 34.6% compared to the same quarter last year. On average, analysts anticipate that Novavax will post ($0.61) earnings per share for the current year.
About Novavax
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
